Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Esophageal Varices-II: Clinical Features and Management

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Too Old for PESI?: Risk Stratification of Octogenarians with Pulmonary Embolism in the Emergency Department.

Seminars in thrombosis and hemostasis·2026

Same author

Hepatic venous pressure gradient, non-invasive tests, and prognosis across the subtypes of advanced steatotic liver disease.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026

Same author

Letter on 'Altered Pathogen Spectrum of Spontaneous Bacterial Peritonitis in Patients Treated With Proton Pump Inhibitors'. Authors' Reply.

Alimentary pharmacology & therapeutics·2026

Same author

Acute HEV Infection Is a Relevant Cause of Decompensation and ACLF in Patients With Liver Cirrhosis.

Liver international : official journal of the International Association for the Study of the Liver·2026

Same author

Particularly strong immune response to influenza vaccination in patients with decompensated liver cirrhosis linked to systemic inflammation.

Frontiers in immunology·2026

Same author

Short- and long-term risk stratification in acutely ill medical patients by implementing D-dimer in the emergency setting - A prospective cohort study.

American heart journal plus : cardiology research and practice·2026

Same journal

Decoding fibrosis: Transcriptomic and clinical insights via AI-derived collagen deposition phenotypes in MASLD.

Hepatology (Baltimore, Md.)·2026

Same journal

A randomized controlled trial of stepped treatment to reduce unhealthy alcohol use in patients with chronic liver disease.

Hepatology (Baltimore, Md.)·2026

Same journal

AASLD AST NASPGHAN Practice Guideline on pediatric liver transplantation: Candidate evaluation.

Hepatology (Baltimore, Md.)·2026

Same journal

H4K12 lactylation drives TREM2high macrophages differentiation in liver fibrosis.

Hepatology (Baltimore, Md.)·2026

Same journal

Good vibrations: Using VCTE to predict hepatic decompensation in MASLD.

Hepatology (Baltimore, Md.)·2026

Same journal

One size does not fit all: Global variability in noninvasive testing for MASLD.

Hepatology (Baltimore, Md.)·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 3, 2025

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

Identification of optimal portal pressure decrease to control ascites while minimizing HE after TIPS: A multicenter

Martin A Kabelitz¹, Lukas Hartl^2,3, Golda Schaub⁴

¹Department for Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.

Hepatology (Baltimore, Md.)

|January 8, 2025

Summary

This summary is machine-generated.

A 60%-80% reduction in portal pressure gradient (PPG) after TIPS effectively controls ascites without increasing overt hepatic encephalopathy (oHE) risk in liver cirrhosis patients.

Keywords:

HE TIPS liver cirrhosis machine learning portal hypertension portal pressure gradient

More Related Videos

Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats

Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats

Published on: August 1, 2018

Porcine Normothermic Isolated Liver Perfusion

Porcine Normothermic Isolated Liver Perfusion

Published on: June 9, 2023

Related Experiment Videos

Last Updated: Jun 3, 2025

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats

Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats

Published on: August 1, 2018

Porcine Normothermic Isolated Liver Perfusion

Porcine Normothermic Isolated Liver Perfusion

Published on: June 9, 2023

Area of Science:

Hepatology
Interventional Radiology
Medical Statistics

Background:

Portal hypertension in liver cirrhosis can cause refractory ascites.
Transjugular intrahepatic portosystemic shunt (TIPS) can manage portal hypertension but may precipitate overt hepatic encephalopathy (oHE).

Purpose of the Study:

To identify the optimal portal pressure gradient (PPG) reduction target via TIPS.
To balance ascites control with the risk of oHE in liver cirrhosis patients.

Main Methods:

Multicenter study of 729 patients undergoing TIPS for refractory ascites.
Utilized competing-risk random survival forest and partial dependence plots.
Divided cohort into derivation (60%) and validation (40%) groups.

Main Results:

Optimal PPG reduction range identified as 60%-80%.
This PPG reduction significantly decreased hepatic decompensations due to ascites (HDA).
No significant increase in oHE incidence was observed within the 60%-80% PPG reduction range.

Conclusions:

A targeted PPG reduction of 60%-80% is effective for managing ascites.
This PPG reduction range offers a favorable balance, reducing HDA without elevating oHE risk.
This PPG reduction target is validated and recommended for clinical practice.